AGWCA
BMRN icon

Annis Gardner Whiting Capital Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Annis Gardner Whiting Capital Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-31
Closed -$1.71K – 1224
2025
Q2 		$1.71K Buy
+31
New +$1.82K ﹤0.01% 984
2024
Q3 		– Sell
-154
Closed -$12.7K – 769
2024
Q2 		$12.7K Hold
154
– – ﹤0.01% 651
2024
Q1 		$13.5K Buy
+154
New +$13.8K ﹤0.01% 630

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Annis Gardner Whiting Capital Advisors's BMRN Position: Q3 2025 in Review

Annis Gardner Whiting Capital Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2025, closing a stake of 31 shares — an estimated $1.71K sold.

Annis Gardner Whiting Capital Advisors first reported a position in BMRN in Q1 2024 and held it in 3 quarters. The position peaked at $13.5K in Q1 2024. 578 funds tracked by Wall St. Rank hold BMRN as of Q3 2025.

  • Annis Gardner Whiting Capital Advisors reported no remaining BioMarin Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Annis Gardner Whiting Capital Advisors sold 31 BioMarin Pharmaceuticals shares in Q3 2025, an estimated $1.71K.
  • Annis Gardner Whiting Capital Advisors first reported a position in BioMarin Pharmaceuticals in Q1 2024 and held it in 3 quarters.
  • Annis Gardner Whiting Capital Advisors's BioMarin Pharmaceuticals position peaked at $13.5K in Q1 2024.
  • 578 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2025.

Based on Annis Gardner Whiting Capital Advisors's 13F filing for Q3 2025, filed 3 Nov 2025.